Research programme: Tumour microenvironment modulators - TuHURA Biosciences
Latest Information Update: 15 Mar 2024
At a glance
- Originator Morphogenesis
- Developer TuHURA Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Immune checkpoint protein inhibitors; Myeloid-derived suppressor cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer